793 related articles for article (PubMed ID: 27892978)
21. Prognostic impacts of extracranial metastasis on non-small cell lung cancer with brain metastasis: A retrospective study based on surveillance, epidemiology, and end results database.
Wang M; Wu Q; Zhang J; Qin G; Yang T; Liu Y; Wang X; Zhang B; Wei Y
Cancer Med; 2021 Jan; 10(2):471-482. PubMed ID: 33320433
[TBL] [Abstract][Full Text] [Related]
22. The effect of non-small cell lung cancer histology on survival as measured by the graded prognostic assessment in patients with brain metastases treated by hypofractionated stereotactic radiotherapy.
Ma LH; Li G; Zhang HW; Wang ZY; Dang J; Zhang S; Yao L
Radiat Oncol; 2016 Jul; 11():92. PubMed ID: 27411944
[TBL] [Abstract][Full Text] [Related]
23. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ
J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700
[TBL] [Abstract][Full Text] [Related]
24. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
25. Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study.
Naik GS; Buchbinder EI; Cohen JV; Manos MP; Johnson AEW; Bowling P; Aizer AA; Schoenfeld JD; Lawrence DP; Haq R; Hodi FS; Sullivan RJ; Ott PA
J Immunother; 2021 Oct; 44(8):307-318. PubMed ID: 34406158
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases.
Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):406-413. PubMed ID: 27598807
[TBL] [Abstract][Full Text] [Related]
27. Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases.
Zerdes I; Kamali C; Koulouris A; Elsayed M; Schnorbach J; Christopoulos P; Tsakonas G
ESMO Open; 2023 Dec; 8(6):102069. PubMed ID: 37988952
[TBL] [Abstract][Full Text] [Related]
28. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.
Sperduto PW; Kased N; Roberge D; Xu Z; Shanley R; Luo X; Sneed PK; Chao ST; Weil RJ; Suh J; Bhatt A; Jensen AW; Brown PD; Shih HA; Kirkpatrick J; Gaspar LE; Fiveash JB; Chiang V; Knisely JP; Sperduto CM; Lin N; Mehta M
J Clin Oncol; 2012 Feb; 30(4):419-25. PubMed ID: 22203767
[TBL] [Abstract][Full Text] [Related]
29. Estimating Survival in Patients with Non-Small-Cell Lung Cancer and Brain Metastases: A Verification of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
Li J; Jing W; Zhai X; Jia W; Zhu H; Yu J
Onco Targets Ther; 2021; 14():1623-1631. PubMed ID: 33688209
[TBL] [Abstract][Full Text] [Related]
30. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS
Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302
[TBL] [Abstract][Full Text] [Related]
31. Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases.
Guo S; Reddy CA; Chao ST; Suh JH; Barnett GH; Vogelbaum MA; Videtic GM
Lung Cancer; 2012 Aug; 77(2):389-93. PubMed ID: 22542706
[TBL] [Abstract][Full Text] [Related]
32. Validation of the Lung-Mol Graded Prognostic Assessment (GPA) System for the Prognosis of Patients Receiving Radiotherapy for Brain Metastasis From Non-small Cell Lung Cancer.
Toriduka D; Matsuo Y; Hanazawa H; Kishi N; Uto M; Mizowaki T
Cureus; 2024 Apr; 16(4):e57485. PubMed ID: 38707125
[TBL] [Abstract][Full Text] [Related]
33. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
34. Comparing survival predicted by the diagnosis-specific Graded Prognostic Assessment (DS-GPA) to actual survival in patients with 1-10 brain metastases treated with stereotactic radiosurgery.
Nagtegaal SHJ; Claes A; Suijkerbuijk KPM; Schramel FMNH; Snijders TJ; Verhoeff JJC
Radiother Oncol; 2019 Sep; 138():173-179. PubMed ID: 31302392
[TBL] [Abstract][Full Text] [Related]
35. Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy.
Shah PP; Franke JL; Medikonda R; Jackson CM; Srivastava S; Choi J; Forde PM; Brahmer JR; Ettinger DS; Feliciano JL; Levy BP; Marrone KA; Naidoo J; Redmond KJ; Kleinberg LR; Lim M
J Neurosurg; 2022 Jan; 136(1):56-66. PubMed ID: 34087798
[TBL] [Abstract][Full Text] [Related]
36. Lung-molGPA Index Predicts Survival Outcomes of Non-Small-Cell Lung Cancer Patients with Synchronous or Metachronous Brain Metastases.
Chen K; Zhang F; Fan Y; Cheng G
Onco Targets Ther; 2020; 13():8837-8844. PubMed ID: 32943887
[TBL] [Abstract][Full Text] [Related]
37. Validation of Recursive Partitioning Analysis and Diagnosis-Specific Graded Prognostic Assessment in patients treated initially with radiosurgery alone.
Likhacheva A; Pinnix CC; Parikh N; Allen PK; Guha-Thakurta N; McAleer M; Sulman EP; Mahajan A; Shiu A; Luo D; Chiu M; Brown PD; Prabhu SS; Chang EL
J Neurosurg; 2012 Dec; 117 Suppl(0):38-44. PubMed ID: 23205787
[TBL] [Abstract][Full Text] [Related]
38. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan.
Yoshida H; Kim YH; Iwatsubo S; Sakaguchi C; Sakamori Y; Nagai H; Ozasa H; Mio T; Hirai T
Oncology; 2020; 98(7):460-467. PubMed ID: 32222702
[TBL] [Abstract][Full Text] [Related]
39. Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study.
Rice SR; Bentzen SM; Hanna A; Choi E; Boggs DH; Kwok Y; Hyder J; Feigenberg SJ; Regine WF; Woodworth GF; Eisenberg HM; Yu C; Biggins TF; Barnholtz-Sloan JS; Sperduto PW; Weltman E; Mehta MP
J Neurooncol; 2018 Nov; 140(2):341-349. PubMed ID: 30132164
[TBL] [Abstract][Full Text] [Related]
40. Real-World Data on Prognostic Factors for Overall Survival in EGFR-Mutant Non-Small-Cell Lung Cancer Patients with Brain Metastases.
Yu X; Fan Y
J Cancer; 2019; 10(15):3486-3493. PubMed ID: 31293653
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
